Immunome, Inc. · NASDAQ:IMNM
Immunome — ASCO 2025
11 slides from Immunome's conference presentation, June 2025
Slide 1: Subgroup Analysis of the Phase 2 Part of the RINGSIDE Phase 2/3 Trial of Varegacestat for Desmoid Tumors
Subgroup Analysis of the Phase 2 Part of the RINGSIDE Phase 2/3 Trial of Varegacestat for Treatment of Desmoid Tumors Rashmi Chugh, MD University of Michigan, Ann Arbor, MI, USA Co-authors: Mrinal Gounder, MD, Arun Singh, MD, Brian A. Van Tine, MD, PhD, Vladimir Andelkovic, MD, Janet Yoon, MD, Edwin
Slide 2: Key Takeaway Points
2 Key Takeaway Points 1 2 In the Phase 2 part of the RINGSIDE Phase 2 results RINGSIDE trial of support continued progressive desmoid evaluation of varegacestat tumors, varegacestat in the double-blind, demonstrated deep randomized, placebo- responses in all subgroups controlled RINGSIDE examined Ph
Slide 3: Background & Methods: Phase 2 of the RINGSIDE Study
3 Background & Methods: Phase 2 of the RINGSIDE Study ● Desmoid tumors (DTs) are rare locally Primary Endpoint: Safety Study start: Oct. 6, 2021 aggressive connective tissue tumors Secondary Endpoint: Tumor volume reduction at Week 16 Data cutoff: Jan. 6, 2025 with variable clinical presentations an
Slide 4: Baseline Characteristics & Safety Summary
Baseline Characteristics & Safety Summary ● 42 participants (pts) enrolled, 29 (69%) entered the OLE ● 8 pts (19%) had a serious adverse event (AE) ● 12 pts (29%) still on treatment ● 9 pts (21%) discontinued due to an AE ● Median time on treatment: 23.3 months (0.7 – 38.8) ● 14 (33%) pts had treatm
Slide 5: ORR and DOR Across Subgroups
ORR and DOR Across Subgroups ORR DOR (weeks) Subgroups n (%) Median (min, max) Across age, tumor size, prior All MRI-evaluable patients (n=37) 24 (65) 58.9 (12.1, 120.6) therapy, tumor location and mutation ≤40 years (n=22) 13 (59) 66.1 (22.1, 110.0) (APC vs CTNNB1) subgroups: Age >40 years (n=15) 1
Slide 6: Tumor Volume Reduction by Age and Mutation Type
Tumor Volume Reduction by Age and Mutation Type Best % Change Patient Age Mutation Type Age N Median % (min, max) Mutation N Median % (min, max) ≤ 40 years 22 -81 (-100, 103) APC 8 -73 (-89, 103) > 40 years 14 -87 (-100, 71) CTNNB1 18 -88 (-100, 49) Abstract #40. Gounder et al. T2-Weighted Signal In
Slide 7: Tumor Volume Reduction by Tumor Size and Location
Tumor Volume Reduction by Tumor Size and Location Best % Change Baseline Tumor Size Tumor Location Size N Median % (min, max) Location N Median % (min, max) < 70 mm 18 -70 (-100, 71) Extra-abdominal 26 -87 (-100, 103) ≥ 70 mm 18 -93 (-100, 103) Intra-abdominal 10 -76 (-95, 49) < 70 mm ≥ 70 mm Extra-
Slide 8: Tumor Volume Reduction by Number of Prior Lines of Therapy
Tumor Volume Reduction by Number of Prior Lines of Therapy Best % Change # of therapies N Median % (min, max) 0 lines 11 -89 (-100, 49) 1 line 12 -77 (-99, 103) 2+ lines 13 -83 (-100, 39) 0 lines 1 line 2+ lines N=36 for tumor volume reduction. Volume results were per blinded independent central rev
Slide 9: Limitations
9 Limitations ● This is a post hoc analysis of outcomes in different patient subgroups ● The sample sizes in each subgroup are relatively small ● We limited our analysis to subgroups with at least 5 patients ● The dosing regimen for patients on 2/4 mg intermittent* changed to 1.2 mg once daily when
Slide 10: Conclusions
10 Conclusions ● In the Phase 2 RINGSIDE study of progressive desmoid tumors, varegacestat demonstrated deep responses in all subgroups examined ● RINGSIDE Phase 2 results support continued evaluation of varegacestat for desmoid tumors in the double-blind, randomized, placebo-controlled RINGSIDE Pha
Slide 11: Lay Summary Slide
11 Lay Summary Slide What did this research tell us? ● In the Phase 2 part of the RINGSIDE study, varegacestat reduced desmoid tumor size in most patients regardless of age, mutation type, tumor size, tumor location, and number of prior therapies Who does this research impact? ● Adults with desmoid